{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T02:44:35Z","timestamp":1781664275100,"version":"3.54.5"},"reference-count":111,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["5P50CA221703-05"],"award-info":[{"award-number":["5P50CA221703-05"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005190","name":"Melanoma Research Alliance","doi-asserted-by":"publisher","award":["687055"],"award-info":[{"award-number":["687055"]}],"id":[{"id":"10.13039\/100005190","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002224","name":"Melanoma Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002224","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["134148-MRAT-19-168-01"],"award-info":[{"award-number":["134148-MRAT-19-168-01"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005984","name":"Dr. Miriam and Sheldon G. Adelson Medical Research Foundation","doi-asserted-by":"publisher","award":["FP17016"],"award-info":[{"award-number":["FP17016"]}],"id":[{"id":"10.13039\/100005984","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","theclinics.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.hoc.2024.05.008","type":"journal-article","created":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T17:48:38Z","timestamp":1717609718000},"page":"1027-1043","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Melanoma Brain Metastasis"],"prefix":"10.1016","volume":"38","author":[{"given":"Merve","family":"Hasanov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuf","family":"Acikgoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.hoc.2024.05.008_bib1","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1200\/JCO.19.01508","article-title":"Cumulative incidence and predictors of CNS metastasis for patients with american joint committee on cancer 8th edition stage III melanoma","volume":"38","author":"Haydu","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.hoc.2024.05.008_bib2","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1200\/JCO.2023.41.16_suppl.2012","article-title":"External validation and nomogram for risk factors of CNS metastasis in patients with clinically localized melanoma","volume":"41","author":"Hasanov","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2024.05.008_bib3","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1002\/cncr.25643","article-title":"Clinical variables and primary tumor characteristics predictive of the development of melanoma brain metastases and post-brain metastases survival","volume":"117","author":"Zakrzewski","year":"2011","journal-title":"Cancer"},{"issue":"15_suppl","key":"10.1016\/j.hoc.2024.05.008_bib4","doi-asserted-by":"crossref","first-page":"9580","DOI":"10.1200\/JCO.2021.39.15_suppl.9580","article-title":"Incidence, timing, and predictors of CNS metastasis in patients (Pts) with clinically localized cutaneous melanoma (CM)","volume":"39","author":"Hasanov","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.hoc.2024.05.008_bib5","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1093\/neuonc\/noac251","article-title":"Changes in outcomes and factors associated with survival in melanoma patients with brain metastases","volume":"25","author":"Hasanov","year":"2023","journal-title":"Neuro Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2024.05.008_bib6","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1002\/cncr.25634","article-title":"Prognostic factors for survival in melanoma patients with brain metastases","volume":"117","author":"Davies","year":"2011","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.hoc.2024.05.008_bib7","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1186\/s12885-018-4374-x","article-title":"Survival and clinical outcomes of patients with melanoma brain metastasis in the era of checkpoint inhibitors and targeted therapies","volume":"18","author":"Vosoughi","year":"2018","journal-title":"BMC Cancer"},{"issue":"12","key":"10.1016\/j.hoc.2024.05.008_bib8","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1002\/cncr.33459","article-title":"Melanoma brain metastasis presentation, treatment, and outcomes in the age of targeted and immunotherapies","volume":"127","author":"Bander","year":"2021","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.hoc.2024.05.008_bib9","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/00002371-200201000-00009","article-title":"Safety and efficacy of high-dose interleukin-2 therapy in patients with brain metastases","volume":"25","author":"Guirguis","year":"2002","journal-title":"J\u00a0Immunother"},{"issue":"5","key":"10.1016\/j.hoc.2024.05.008_bib10","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(12)70090-6","article-title":"Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial","volume":"13","author":"Margolin","year":"2012","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2024.05.008_bib11","article-title":"Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10\u00a0mg\/kg with 3\u00a0mg\/kg in patients with advanced melanoma","volume":"8","author":"Ascierto","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"issue":"5","key":"10.1016\/j.hoc.2024.05.008_bib12","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S1470-2045(17)30231-0","article-title":"Ipilimumab 10\u00a0mg\/kg versus ipilimumab 3\u00a0mg\/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial","volume":"18","author":"Ascierto","year":"2017","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2024.05.008_bib13","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1200\/JCO.18.00204","article-title":"Long-term survival of patients with melanoma with active brain metastases treated with pembrolizumab on a phase II trial","volume":"37","author":"Kluger","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2024.05.008_bib14","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S1470-2045(18)30139-6","article-title":"Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study","volume":"19","author":"Long","year":"2018","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2024.05.008_bib15","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1805453","article-title":"Combined nivolumab and ipilimumab in melanoma metastatic to the brain","volume":"379","author":"Tawbi","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.hoc.2024.05.008_bib16","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1016\/S1470-2045(21)00545-3","article-title":"Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study","volume":"22","author":"Tawbi","year":"2021","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.hoc.2024.05.008_bib17","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1093\/neuonc\/noab094","article-title":"Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204)","volume":"23","author":"Tawbi","year":"2021","journal-title":"Neuro Oncol"},{"issue":"17","key":"10.1016\/j.hoc.2024.05.008_bib18","doi-asserted-by":"crossref","first-page":"4737","DOI":"10.1158\/1078-0432.CCR-21-1046","article-title":"Primary analysis and 4-year follow-up of the phase III NIBIT-M2 trial in melanoma patients with brain metastases","volume":"27","author":"Di Giacomo","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hoc.2024.05.008_bib19","doi-asserted-by":"crossref","first-page":"113531","DOI":"10.1016\/j.ejca.2024.113531","article-title":"Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial","volume":"199","author":"Di Giacomo","year":"2024","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.hoc.2024.05.008_bib20","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s11060-014-1400-y","article-title":"Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases","volume":"118","author":"Queirolo","year":"2014","journal-title":"J\u00a0Neuro Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2024.05.008_bib21","first-page":"227","article-title":"Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival","volume":"117","author":"Knisely","year":"2012","journal-title":"J\u00a0Neurosurg"},{"issue":"6","key":"10.1016\/j.hoc.2024.05.008_bib22","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/cam4.140","article-title":"Ipilimumab and radiation therapy for melanoma brain metastases","volume":"2","author":"Silk","year":"2013","journal-title":"Cancer Med"},{"issue":"1","key":"10.1016\/j.hoc.2024.05.008_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/cam4.315","article-title":"Survival of melanoma patients with brain metastases treated with ipilimumab and stereotactic radiosurgery","volume":"4","author":"Tazi","year":"2015","journal-title":"Cancer Med"},{"issue":"26","key":"10.1016\/j.hoc.2024.05.008_bib24","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.hoc.2024.05.008_bib25","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/S1470-2045(19)30388-2","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study","volume":"20","author":"Robert","year":"2019","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2024.05.008_bib26","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.hoc.2024.05.008_bib27","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.21.02229","article-title":"Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma","volume":"40","author":"Wolchok","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.hoc.2024.05.008_bib28","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1470-2045(16)30053-5","article-title":"Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial","volume":"17","author":"Goldberg","year":"2016","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2024.05.008_bib29","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.hoc.2024.05.008_bib30","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S1470-2045(12)70431-X","article-title":"Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial","volume":"13","author":"Long","year":"2012","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2024.05.008_bib31","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1093\/annonc\/mdw641","article-title":"Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study","volume":"28","author":"McArthur","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hoc.2024.05.008_bib32","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.ejca.2017.04.007","article-title":"Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAF(V600) mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis","volume":"79","author":"Blank","year":"2017","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.hoc.2024.05.008_bib33","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.ejca.2013.11.002","article-title":"Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study","volume":"50","author":"Dummer","year":"2014","journal-title":"Eur J Cancer"},{"issue":"7","key":"10.1016\/j.hoc.2024.05.008_bib34","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S1470-2045(17)30429-1","article-title":"Dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial","volume":"18","author":"Davies","year":"2017","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.hoc.2024.05.008_bib35","doi-asserted-by":"crossref","first-page":"e461","DOI":"10.1016\/S1470-2045(23)00334-0","article-title":"Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study","volume":"24","author":"Dummer","year":"2023","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2024.05.008_bib36","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1158\/1078-0432.CCR-22-2581","article-title":"Clinical features associated with outcomes and biomarker analysis of dabrafenib plus trametinib treatment in patients with BRAF-mutant melanoma brain metastases","volume":"29","author":"Wilmott","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.hoc.2024.05.008_bib37","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1002\/1097-0142(19901101)66:9<1873::AID-CNCR2820660904>3.0.CO;2-5","article-title":"Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases","volume":"66","author":"Jacquillat","year":"1990","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.hoc.2024.05.008_bib38","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1093\/annonc\/mdl148","article-title":"Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG\/ADO study","volume":"17","author":"Schadendorf","year":"2006","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.hoc.2024.05.008_bib39","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1200\/JCO.2004.11.044","article-title":"Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study","volume":"22","author":"Agarwala","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2024.05.008_bib40","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2217\/cns.14.40","article-title":"Whole-brain radiotherapy in patients with brain metastases from melanoma","volume":"3","author":"de la Fuente","year":"2014","journal-title":"CNS Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2024.05.008_bib41","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/sj.bjc.6602018","article-title":"A\u00a0prognostic index that predicts outcome following palliative whole brain radiotherapy for patients with metastatic malignant melanoma","volume":"91","author":"Morris","year":"2004","journal-title":"Br J Cancer"},{"issue":"9422","key":"10.1016\/j.hoc.2024.05.008_bib42","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(04)16250-8","article-title":"Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial","volume":"363","author":"Andrews","year":"2004","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.hoc.2024.05.008_bib43","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/S1470-2045(09)70263-3","article-title":"Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial","volume":"10","author":"Chang","year":"2009","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2024.05.008_bib44","first-page":"457","article-title":"Survival among patients with 10 or more brain metastases treated with stereotactic radiosurgery","volume":"119","author":"Rava","year":"2013","journal-title":"J\u00a0Neurosurg"},{"issue":"6","key":"10.1016\/j.hoc.2024.05.008_bib45","first-page":"1250","article-title":"Gamma Knife surgery for the treatment of 5 to 15 metastases to the brain: clinical article","volume":"118","author":"Salvetti","year":"2013","journal-title":"J\u00a0Neurosurg"},{"issue":"4","key":"10.1016\/j.hoc.2024.05.008_bib46","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S1470-2045(14)70061-0","article-title":"Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study","volume":"15","author":"Yamamoto","year":"2014","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2024.05.008_bib47","doi-asserted-by":"crossref","first-page":"215","DOI":"10.4103\/0973-1482.98973","article-title":"Linear accelerator based stereotactic radiosurgery for melanoma brain metastases","volume":"8","author":"Bernard","year":"2012","journal-title":"J\u00a0Cancer Res Therapeut"},{"issue":"5","key":"10.1016\/j.hoc.2024.05.008_bib48","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1097\/COC.0000000000000299","article-title":"Survival of patients with multiple intracranial metastases treated with stereotactic radiosurgery: does the number of tumors matter?","volume":"41","author":"Knoll","year":"2018","journal-title":"Am J Clin Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2024.05.008_bib49","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0360-3016(98)00272-7","article-title":"Stereotactic radiosurgery for cerebral metastatic melanoma: factors affecting local disease control and survival","volume":"42","author":"Mori","year":"1998","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"33","key":"10.1016\/j.hoc.2024.05.008_bib50","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1200\/JCO.19.01414","article-title":"Adjuvant whole-brain radiation therapy compared with observation after local treatment of melanoma brain metastases: a multicenter, randomized phase III trial","volume":"37","author":"Hong","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2024.05.008_bib51","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S1470-2045(17)30441-2","article-title":"Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C\/CEC.3): a multicentre, randomised, controlled, phase 3 trial","volume":"18","author":"Brown","year":"2017","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2024.05.008_bib52","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/S1470-2045(17)30414-X","article-title":"Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial","volume":"18","author":"Mahajan","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.hoc.2024.05.008_bib53","doi-asserted-by":"crossref","first-page":"439752","DOI":"10.1155\/2011\/439752","article-title":"The confluence of stereotactic ablative radiotherapy and tumor immunology","volume":"2011","author":"Finkelstein","year":"2011","journal-title":"Clin Dev Immunol"},{"issue":"10","key":"10.1016\/j.hoc.2024.05.008_bib54","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1056\/NEJMoa1112824","article-title":"Immunologic correlates of the abscopal effect in a patient with melanoma","volume":"366","author":"Postow","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.hoc.2024.05.008_bib55","doi-asserted-by":"crossref","first-page":"e1283461","DOI":"10.1080\/2162402X.2017.1283461","article-title":"Improved time to disease progression in the brain in patients with melanoma brain metastases treated with concurrent delivery of radiosurgery and ipilimumab","volume":"6","author":"Skrepnik","year":"2017","journal-title":"OncoImmunology"},{"key":"10.1016\/j.hoc.2024.05.008_bib56","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.radonc.2018.08.025","article-title":"Treatment of brain metastases with stereotactic radiosurgery and immune checkpoint inhibitors: An international meta-analysis of individual patient data","volume":"130","author":"Lehrer","year":"2019","journal-title":"Radiother Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2024.05.008_bib57","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1097\/COC.0000000000000199","article-title":"Ipilimumab and stereotactic radiosurgery versus stereotactic radiosurgery alone for newly diagnosed melanoma brain metastases","volume":"40","author":"Patel","year":"2017","journal-title":"Am J Clin Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2024.05.008_bib58","first-page":"17","article-title":"Does immunotherapy increase the rate of radiation necrosis after radiosurgical treatment of brain metastases?","volume":"125","author":"Colaco","year":"2016","journal-title":"J\u00a0Neurosurg"},{"issue":"4","key":"10.1016\/j.hoc.2024.05.008_bib59","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/pcmr.12682","article-title":"Survival and prognostic factors for patients with melanoma brain metastases in the era of modern systemic therapy","volume":"31","author":"Tio","year":"2018","journal-title":"Pigment Cell Melanoma Res"},{"issue":"5","key":"10.1016\/j.hoc.2024.05.008_bib60","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1634\/theoncologist.2018-0306","article-title":"Upfront surgical resection of melanoma brain metastases provides a bridge toward immunotherapy-mediated systemic control","volume":"24","author":"Alvarez-Breckenridge","year":"2019","journal-title":"Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2024.05.008_bib61","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.ccell.2017.02.009","article-title":"The microenvironmental landscape of brain tumors","volume":"31","author":"Quail","year":"2017","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.hoc.2024.05.008_bib62","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.4049\/jimmunol.157.5.1819","article-title":"The central nervous system as an immunocompetent organ: role of glial cells in antigen presentation","volume":"157","author":"Shrikant","year":"1996","journal-title":"J\u00a0Immunol"},{"issue":"5726","key":"10.1016\/j.hoc.2024.05.008_bib63","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1126\/science.1110647","article-title":"Resting microglial cells are highly dynamic surveillants of brain parenchyma in\u00a0vivo","volume":"308","author":"Nimmerjahn","year":"2005","journal-title":"Science"},{"issue":"14","key":"10.1016\/j.hoc.2024.05.008_bib64","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1016\/j.cell.2022.06.007","article-title":"Dissecting the treatment-naive ecosystem of human melanoma brain metastasis","volume":"185","author":"Biermann","year":"2022","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.hoc.2024.05.008_bib65","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41568-019-0220-y","article-title":"Brain metastasis","volume":"20","author":"Boire","year":"2020","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"10.1016\/j.hoc.2024.05.008_bib66","article-title":"Unveiling the tumor immune microenvironment of organ-specific melanoma metastatic sites","volume":"10","author":"Conway","year":"2022","journal-title":"J\u00a0Immunother Cancer"},{"issue":"1","key":"10.1016\/j.hoc.2024.05.008_bib67","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41568-019-0205-x","article-title":"The blood-brain barrier and blood-tumour barrier in brain tumours and metastases","volume":"20","author":"Arvanitis","year":"2020","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1016\/j.hoc.2024.05.008_bib68","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11060-020-03619-0","article-title":"Melanoma brain metastases have lower T-cell content and microvessel density compared to matched extracranial metastases","volume":"152","author":"Weiss","year":"2021","journal-title":"J\u00a0Neuro Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2024.05.008_bib69","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/s43018-022-00338-5","article-title":"The interaction of CD4(+) helper T\u00a0cells with dendritic cells shapes the tumor microenvironment and immune checkpoint blockade response","volume":"3","author":"Cohen","year":"2022","journal-title":"Nat Cancer"},{"issue":"3","key":"10.1016\/j.hoc.2024.05.008_bib70","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ccell.2022.02.002","article-title":"Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer","volume":"40","author":"Patil","year":"2022","journal-title":"Cancer Cell"},{"issue":"2\u20133","key":"10.1016\/j.hoc.2024.05.008_bib71","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.neuint.2003.08.014","article-title":"Cerebral glucose metabolism and the glutamine cycle as detected by in\u00a0vivo and in\u00a0vitro 13C NMR spectroscopy","volume":"45","author":"Garcia-Espinosa","year":"2004","journal-title":"Neurochem Int"},{"issue":"1","key":"10.1016\/j.hoc.2024.05.008_bib72","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1007\/s12031-007-0059-7","article-title":"Brain uptake and utilization of fatty acids, lipids & lipoproteins: recommendations for future research","volume":"33","author":"Katz","year":"2007","journal-title":"J\u00a0Mol Neurosci"},{"issue":"Pt 1","key":"10.1016\/j.hoc.2024.05.008_bib73","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1258\/000456306775141759","article-title":"Reference data for cerebrospinal fluid and the utility of amino acid measurement for the diagnosis of inborn errors of metabolism","volume":"43","author":"Jones","year":"2006","journal-title":"Ann Clin Biochem"},{"issue":"1","key":"10.1016\/j.hoc.2024.05.008_bib74","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1023\/B:NERE.0000010461.34920.0c","article-title":"Plasma and cerebrospinal fluid amino acids in epileptic patients","volume":"29","author":"Rainesalo","year":"2004","journal-title":"Neurochem Res"},{"issue":"1","key":"10.1016\/j.hoc.2024.05.008_bib75","first-page":"vdaa177","article-title":"Clinical, molecular, metabolic, and immune features associated with oxidative phosphorylation in melanoma brain metastases","volume":"3","author":"Fischer","year":"2021","journal-title":"Neurooncol Adv"},{"issue":"5","key":"10.1016\/j.hoc.2024.05.008_bib76","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1158\/2159-8290.CD-18-1489","article-title":"Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases","volume":"9","author":"Fischer","year":"2019","journal-title":"Cancer Discov"},{"issue":"23","key":"10.1016\/j.hoc.2024.05.008_bib77","doi-asserted-by":"crossref","first-page":"7037","DOI":"10.1158\/0008-5472.CAN-14-1392","article-title":"Inhibition of mTORC1\/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1alpha and oxidative phosphorylation in melanoma","volume":"74","author":"Gopal","year":"2014","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.hoc.2024.05.008_bib78","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.ccr.2013.02.003","article-title":"Oncogenic BRAF regulates oxidative metabolism via PGC1alpha and MITF","volume":"23","author":"Haq","year":"2013","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.hoc.2024.05.008_bib79","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.124989","article-title":"Tumor cell oxidative metabolism as a barrier to PD-1 blockade immunotherapy in melanoma","volume":"4","author":"Najjar","year":"2019","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.hoc.2024.05.008_bib80","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1158\/2326-6066.CIR-16-0103","article-title":"Efficacy of PD-1 blockade is potentiated by metformin-induced reduction of tumor hypoxia","volume":"5","author":"Scharping","year":"2017","journal-title":"Cancer Immunol Res"},{"issue":"12","key":"10.1016\/j.hoc.2024.05.008_bib81","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1158\/2159-8290.CD-19-0270","article-title":"Polyunsaturated fatty acids from astrocytes activate ppargamma signaling in cancer cells to promote brain metastasis","volume":"9","author":"Zou","year":"2019","journal-title":"Cancer Discov"},{"issue":"4","key":"10.1016\/j.hoc.2024.05.008_bib82","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.plipres.2011.06.002","article-title":"Cholesterol metabolism in neurons and astrocytes","volume":"50","author":"Pfrieger","year":"2011","journal-title":"Prog Lipid Res"},{"issue":"11","key":"10.1016\/j.hoc.2024.05.008_bib83","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1177\/0271678X15609331","article-title":"Brain interstitial fluid glutamine homeostasis is controlled by blood-brain barrier SLC7A5\/LAT1 amino acid transporter","volume":"36","author":"Dolgodilina","year":"2016","journal-title":"J\u00a0Cerebr Blood Flow Metabol"},{"issue":"1","key":"10.1016\/j.hoc.2024.05.008_bib84","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1172\/JCI118043","article-title":"Interstitial fluid concentrations of glycerol, glucose, and amino acids in human quadricep muscle and adipose tissue. Evidence for significant lipolysis in skeletal muscle","volume":"96","author":"Maggs","year":"1995","journal-title":"J\u00a0Clin Invest"},{"issue":"9","key":"10.1016\/j.hoc.2024.05.008_bib85","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1158\/2159-8290.CD-19-1228","article-title":"Limited environmental serine and glycine confer brain metastasis sensitivity to PHGDH inhibition","volume":"10","author":"Ngo","year":"2020","journal-title":"Cancer Discov"},{"issue":"7","key":"10.1016\/j.hoc.2024.05.008_bib86","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","article-title":"Genomic classification of cutaneous melanoma","volume":"161","author":"Cancer Genome Atlas","year":"2015","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.hoc.2024.05.008_bib87","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.bcp.2011.05.015","article-title":"Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma","volume":"82","author":"Fedorenko","year":"2011","journal-title":"Biochem Pharmacol"},{"issue":"25","key":"10.1016\/j.hoc.2024.05.008_bib88","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1038\/onc.2012.453","article-title":"NRAS mutant melanoma: biological behavior and future strategies for therapeutic management","volume":"32","author":"Fedorenko","year":"2013","journal-title":"Oncogene"},{"issue":"9","key":"10.1016\/j.hoc.2024.05.008_bib89","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1038\/ng.3361","article-title":"Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas","volume":"47","author":"Krauthammer","year":"2015","journal-title":"Nat Genet"},{"issue":"3","key":"10.1016\/j.hoc.2024.05.008_bib90","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2217\/mmt.15.18","article-title":"Converting biology into clinical benefit: lessons learned from BRAF inhibitors","volume":"2","author":"McQuade","year":"2015","journal-title":"Melanoma Manag"},{"issue":"6892","key":"10.1016\/j.hoc.2024.05.008_bib91","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"issue":"16","key":"10.1016\/j.hoc.2024.05.008_bib92","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.1002\/cncr.26724","article-title":"NRAS mutation status is an independent prognostic factor in metastatic melanoma","volume":"118","author":"Jakob","year":"2012","journal-title":"Cancer"},{"issue":"20","key":"10.1016\/j.hoc.2024.05.008_bib93","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1200\/JCO.2011.41.2452","article-title":"BRAF\/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma","volume":"30","author":"Colombino","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2024.05.008_bib94","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13040731","article-title":"Integrative genomic analyses of patient-matched intracranial and extracranial metastases reveal a novel brain-specific landscape of genetic variants in driver genes of malignant melanoma","volume":"13","author":"Varaljai","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"21","key":"10.1016\/j.hoc.2024.05.008_bib95","doi-asserted-by":"crossref","first-page":"5537","DOI":"10.1158\/1078-0432.CCR-13-3003","article-title":"Molecular profiling of patient-matched brain and extracranial melanoma metastases implicates the PI3K pathway as a therapeutic target","volume":"20","author":"Chen","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.hoc.2024.05.008_bib96","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1002\/ijc.30241","article-title":"BRAF-V600 mutational status affects recurrence patterns of melanoma brain metastasis","volume":"140","author":"Maxwell","year":"2017","journal-title":"Int J Cancer"},{"key":"10.1016\/j.hoc.2024.05.008_bib97","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ejca.2022.08.008","article-title":"Cumulative incidence and risk factors of brain metastasis for acral and mucosal melanoma patients with stages I-III","volume":"175","author":"Wang","year":"2022","journal-title":"Eur J Cancer"},{"issue":"24","key":"10.1016\/j.hoc.2024.05.008_bib98","doi-asserted-by":"crossref","first-page":"7538","DOI":"10.1158\/1078-0432.CCR-09-1985","article-title":"Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma","volume":"15","author":"Davies","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.hoc.2024.05.008_bib99","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/cam4.50","article-title":"Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases","volume":"2","author":"Niessner","year":"2013","journal-title":"Cancer Med"},{"issue":"21","key":"10.1016\/j.hoc.2024.05.008_bib100","doi-asserted-by":"crossref","first-page":"5527","DOI":"10.1158\/1078-0432.CCR-14-1027","article-title":"Complete loss of PTEN protein expression correlates with shorter time to brain metastasis and survival in stage IIIB\/C melanoma patients with BRAFV600 mutations","volume":"20","author":"Bucheit","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.hoc.2024.05.008_bib101","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.celrep.2015.09.057","article-title":"AKT1 activation promotes development of melanoma metastases","volume":"13","author":"Cho","year":"2015","journal-title":"Cell Rep"},{"issue":"23","key":"10.1016\/j.hoc.2024.05.008_bib102","doi-asserted-by":"crossref","first-page":"5818","DOI":"10.1158\/1078-0432.CCR-16-0064","article-title":"PI3K pathway inhibition achieves potent antitumor activity in melanoma brain metastases in\u00a0vitro and in\u00a0vivo","volume":"22","author":"Niessner","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.hoc.2024.05.008_bib103","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/pcmr.12538","article-title":"Melanoma central nervous system metastases: current approaches, challenges, and opportunities","volume":"29","author":"Cohen","year":"2016","journal-title":"Pigment Cell Melanoma Res"},{"issue":"3","key":"10.1016\/j.hoc.2024.05.008_bib104","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s11060-019-03121-2","article-title":"Predictors of survival in metastatic melanoma patients with leptomeningeal disease (LMD)","volume":"142","author":"Ferguson","year":"2019","journal-title":"J\u00a0Neuro Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2024.05.008_bib105","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/s41591-022-02170-x","article-title":"Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results","volume":"29","author":"Glitza","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.hoc.2024.05.008_bib106","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2023.09.2216","article-title":"10820 - Concurrent intrathecal (IT) and intravenous (IV) nivolumab (N) for melanoma (MM) patients (pts) with leptomeningeal disease (LMD)","author":"Glitza","year":"2023","journal-title":"Annals of Oncology. ESMO"},{"issue":"3","key":"10.1016\/j.hoc.2024.05.008_bib107","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s11060-017-2472-2","article-title":"Rapid resolution of leptomeningeal disease with targeted therapy in a metastatic melanoma patient","volume":"133","author":"Glitza","year":"2017","journal-title":"J\u00a0Neuro Oncol"},{"key":"10.1016\/j.hoc.2024.05.008_bib108","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1186\/s12885-015-1391-x","article-title":"Prolonged survival of a patient with metastatic leptomeningeal melanoma treated with BRAF inhibition-based therapy: a case report","volume":"15","author":"Kim","year":"2015","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.hoc.2024.05.008_bib109","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/CMR.0b013e32835e589c","article-title":"Long-term stabilization of leptomeningeal disease with whole-brain radiation therapy in a patient with metastatic melanoma treated with vemurafenib: a case report","volume":"23","author":"Lee","year":"2013","journal-title":"Melanoma Res"},{"issue":"14","key":"10.1016\/j.hoc.2024.05.008_bib110","doi-asserted-by":"crossref","first-page":"4109","DOI":"10.1158\/1078-0432.CCR-21-1694","article-title":"Single-cell characterization of the immune microenvironment of melanoma brain and leptomeningeal metastases","volume":"27","author":"Smalley","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.hoc.2024.05.008_bib111","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.cell.2017.02.025","article-title":"Complement component 3 adapts the cerebrospinal fluid for leptomeningeal metastasis","volume":"168","author":"Boire","year":"2017","journal-title":"Cell"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858824000571?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858824000571?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T20:24:05Z","timestamp":1725049445000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858824000571"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":111,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S0889858824000571"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2024.05.008","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Melanoma Brain Metastasis","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2024.05.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}